Universal Biosensors Pty Ltd ABN 35 098 234 309

1 Corporate Avenue Rowville VIC 3178 Australia

Telephone +61 3 9213 9000 Facsimile +61 3 9213 9099 Email secretary@universalbiosensors.com www.universalbiosensors.com



21 February 2011

Update on Regulatory Process in the United States for OneTouch Verio®

Universal Biosensors, Inc. (ASX: UBI) has been advised by LifeScan, Inc. that LifeScan has been granted regulatory clearance to sell the OneTouch Verio[®] product as sold in Australia by the United States Food and Drug Administration.

Chairman and Interim CEO, Andrew Denver noted "We are pleased that the FDA has approved the Verio system. It is another step in the commercialisation of the UBI developed product. However it must be noted that LifeScan have not disclosed their plans for a US launch, a decision which is solely within their control."

Ends

Enquiries: Mr Andrew Denver: 03 9213 9000

About Universal Biosensors

For additional information in relation to Universal Biosensors, refer to <u>http://www.universalbiosensors.com/announcements.html</u>.

Universal Biosensors is a specialist medical diagnostics company, founded in 2001, that is focused on the development, manufacture and commercialisation of a range of *in vitro* diagnostic tests for point-of-care use. These tests capitalise on a technology platform which uses a novel electrochemical cell that can be adapted for multiple analytes and provide for enhanced measurements in whole blood.

Universal Biosensors' first product, developed in conjunction with LifeScan, Inc., is a next generation test for diabetics to self-monitor blood glucose. The product features market leading accuracy and was launched in The Netherlands, Australia, Italy and France. The relationship with LifeScan, Inc. dates from 2001. In 2009 the two companies entered into an updated Master Services and Supply Agreement under which Universal Biosensors agreed to be a non-exclusive manufacturer of blood glucose sensor strips for LifeScan.

Universal Biosensors is currently developing other point-of-care blood tests from its technology platform, which it intends to partner in due course.